Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma

Trial Profile

Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Porfimer sodium (Primary)
  • Indications Cholangiocarcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms OPUS
  • Sponsors Concordia Pharmaceuticals
  • Most Recent Events

    • 19 Dec 2016 According to a Concordia International media release, company has decided to terminate enrollment for this trial. Patients currently enrolled in the phase 3 trial will continue through to completion.
    • 19 Dec 2016 Status changed from recruiting to discontinued.
    • 23 Sep 2014 New source identified and integrated: ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top